Free Trial
NASDAQ:NDRA

ENDRA Life Sciences (NDRA) Stock Price, News & Analysis

ENDRA Life Sciences logo
$7.41 +0.42 (+6.01%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$7.28 -0.13 (-1.75%)
As of 10/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ENDRA Life Sciences Stock (NASDAQ:NDRA)

Advanced

Key Stats

Today's Range
$7.10
$8.00
50-Day Range
$4.09
$8.12
52-Week Range
$2.90
$22.68
Volume
162,942 shs
Average Volume
741,871 shs
Market Capitalization
$5.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00
Consensus Rating
Hold

Company Overview

ENDRA Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

NDRA MarketRank™: 

ENDRA Life Sciences scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ENDRA Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    ENDRA Life Sciences has a consensus price target of $50.00, representing about 574.8% upside from its current price of $7.41.

  • Amount of Analyst Coverage

    ENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about ENDRA Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for ENDRA Life Sciences are expected to grow in the coming year, from ($47.46) to ($15.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ENDRA Life Sciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ENDRA Life Sciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ENDRA Life Sciences has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ENDRA Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.03% of the float of ENDRA Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ENDRA Life Sciences has recently increased by 2.82%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    ENDRA Life Sciences does not currently pay a dividend.

  • Dividend Growth

    ENDRA Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.03% of the float of ENDRA Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    ENDRA Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ENDRA Life Sciences has recently increased by 2.82%, indicating that investor sentiment is decreasing.
  • News Sentiment

    ENDRA Life Sciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for ENDRA Life Sciences this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for NDRA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.04% of the stock of ENDRA Life Sciences is held by insiders.

  • Percentage Held by Institutions

    Only 1.19% of the stock of ENDRA Life Sciences is held by institutions.

  • Read more about ENDRA Life Sciences' insider trading history.
Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NDRA Stock News Headlines

ENDRA Life Sciences (NASDAQ:NDRA) Stock Price Up 25.3% - Here's Why
What’s Driving The Rally In NDRA Stock Today?
The 7 Warning Signals Flashing Red Right Now
A free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC.tc pixel
See More Headlines

NDRA Stock Analysis - Frequently Asked Questions

ENDRA Life Sciences' stock was trading at $6.26 at the beginning of 2025. Since then, NDRA stock has increased by 18.4% and is now trading at $7.41.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($1.71) EPS for the quarter, beating analysts' consensus estimates of ($2.27) by $0.56.

ENDRA Life Sciences's stock reverse split before market open on Tuesday, August 20th 2024.The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL).

Company Calendar

Last Earnings
8/14/2025
Today
10/15/2025
Next Earnings (Estimated)
11/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NDRA
CIK
1681682
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$50.00
Low Price Target
$50.00
Potential Upside/Downside
+574.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($33.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.51 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-194.14%
Return on Assets
-127.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.21
Quick Ratio
3.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.77 per share
Price / Book
1.55

Miscellaneous

Outstanding Shares
750,000
Free Float
753,000
Market Cap
$5.56 million
Optionable
Not Optionable
Beta
-0.09
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:NDRA) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners